Dext

rose

5%

Sodi

um C

hlor

ide

Acyc

lovi

r

Amik

acin

Amio

daro

ne

Azith

rom

ycin

Aztre

onam

Bum

etan

ide

Calc

ium

chl

orid

e

Calc

ium

glu

cona

te

Cefa

zolin

Cefe

pim

e

Ceftr

iaxo

ne

Cim

etid

ine

Cipr

oflo

xaci

n

Cisa

tracu

rium

Dexa

met

haso

ne

Digo

xin

Dilti

azem

Diph

enhy

dram

ine

Dobu

tam

ine

Dopa

min

e

Enal

april

Epin

ephr

ine

Esm

olol

Fam

otid

ine

Fent

anyl

Fluc

onaz

ole

Furo

sem

ide

Gent

amic

in

Hepa

rin

Hydr

ocor

tison

e

Hydr

omor

phon

e

Imip

enem

Insu

lin, R

egul

ar

Keto

rola

c

Labe

talo

l

Lans

opra

zole

Levo

floxa

cin

Line

zolid

Lore

zepa

m

Mag

nesi

um S

O 4

Man

nito

l

Mer

open

em

Met

hylp

redn

isol

one

Met

oclo

pram

ide

Met

opro

lol

Met

roni

dazo

le

Mid

azol

am

Milr

inon

e

Mor

phin

e

Mul

tivita

min

s

Nitro

glyc

erin

Nitro

prus

side

Nore

pine

phrin

e

Onda

nset

ron

Pant

opra

zole

Phen

ylep

hrin

e

Pipe

raci

llin/

Tazo

bact

am

Pota

ssiu

m C

hlor

ide

Prop

ofol

Rani

tidin

e

Sodi

um B

icar

bona

te

Tobr

amyc

in

Vanc

omyc

in

Vaso

pres

sin

Vecu

roni

um

AcyclovirAmikacinAmiodaroneAzithromycinAztreonamBumetanideCalcium chlorideCalcium gluconateCefazolinCefepimeCeftriaxoneCimetidineCiprofloxacinCisatracuriumDexamethasoneDigoxinDiltiazemDiphenhydramineDobutamineDopamineEnalaprilEpinephrineEsmololFamotidineFentanylFluconazoleFurosemideGentamicinHeparinHydrocortisoneHydromorphoneImipenemInsulin, Regular

CCCCCCCCCCCCCCCCCCCCCCCCCCNCCCCNC

CCNCCCCCCCCCCCCCCCCCCCCCCNCCCCCCC

CNNICNCCICCICCNNCIICIICCCCCCCCCC

CCICCCCCCCICCCNCCCCCCCCCCCCICCCN

NCNNCCCNNCNCNNICNCCNCCCCCNCINNIC

NININNNNNININNNNCNNNNNIINIINNNIN

ICNI

CNCCCCCCCCNCNCCCCCCCCCCCCCNC

CCCNCNNCCCNNCCNCCNCCCCCCCCCCCCCC

NCCNNNNNNNNNNNNNNCCNCCNNNNNNCNNN

CCCNCNNCCINCCINCCNCCCCCCNCCCNCNC

CCNNCCNCNCNNICNCIIICCCNCCCNCCNCC

ICNNCCNCNNNINCNIIIIINNINCCNCCCCC

CCCICCNICNNNCCNCIICCCCNCNCNCCCIC

CINNCNNNNNNNCCCCCCNCCCNCCCNCNCNN

ICCICNNCNINNCICCCCCNNNNNCICIICNN

CCNNCCNCINCCCCCCCCCCCCCCCICICCCN

CCNNCCNICCCCICNCIICCCICCCCICCNCC

NNINNNNNNNNCCCNCNINNNCCCINNCNNNC

NCCNCCNCCICCCCCCCCCCCCCCCICNNCCI

CCNCNCNCIIICCCINCCCCCCCCCICNNCCI

ICCNCNCNIIICCCIICCCCCCCCCICIICNI

ICCNCCCCIICNCCCNCCCCCCCCCICCCCCN

CCNNCCNCCICCNCCNCCCCCCCCCCCCCCCC

ICCNCCCCCNCCNCCNCCCCCCCCCCCCCCCN

ICCNCCCCCNCCNCICCCCCCCCCCICNNCCC

CCCICCNCNINNNCCCCCCCCCCCCICCCCCN

CCCICCNCCNCCNCCCCCCCCCCCCCCCCCCC

CCCNCCNNCCNCCCCICCCCCCCCCICCCCIC

CCNICCNCCCCCIICNIIIICCIICI

ICCCCC

CCCICCNCNNNNCCINCCCCCCCCCCI

IICCN

CIINCCNCCCCCIICCNNICCCNCCCCI

NNCC

CCNNCCCNCCCNICCNNNICCCNCCCCINCCC

CCNNCCNCNCCCCCNNCCCCCCCCCCCCNCCC

CCIINCNNCCINNCCNCCNCCCCCCICCCCCC

CNCNCCNCCCCNNNCCIIINCNCNCCCNCCCC

NNNINNNNNNNNNCCNNNNNNNNNCNNNNNCNN

ICCNCCNCNNICNNINCCCCCCCCCCNCNICCI

NCNNINNIIICNINCNIIIIINIICCICCIIIN

ICIICCNCICCCNNCNCCCCCCCCCCICICCCI

CCCNCCNCCCNCCCCCCCCCCCCCCCCCCCCCC

CCCNICNCCCCCCCCNCCCCCCCCCCCCCCCIC

CCNNCCICNIINICCNCCNCCCCCCCNCCNCCC

CCNNCCNCCICNNCCNCCCCCCCCCCCCCCCIC

INNNNNNCNNNCNNCCCCCCCNNNNCCCCNCNC

CCCNCCNICCCCIICNIICCCCNCCCCCCNCCC

CCNNCCNNCICNCCCNCCCCCCCCCCICCCCCC

NNNNNNNNNNNCNNNNNNNNNNNNNNNNNNNNN

CCNNINNNCCCCCCNNCNNCCNCNNCNNCCCNN

ICCNCINCCICCCCICCCICCCCCCCICCICIN

CCCNNCCCCCNCCNCCCNCCCCNNCNICCNCIC

ICCICCCCCICCNCCCCCCCCCCCCCICNNCCN

NNNNNNCNINNNNNCNNNNNNCNNNNNCNNNNN

CCCNCCNCCNCNNCCNCCCCCCCCCCCCCCCCC

ICNNCCCCCNCCNICNCINCCCCCCCCCCCCNC

NCCNCCCCCNCNCCCNCCCCCCCCCCNCCCCCI

ICNCCCNCCINCCCCNCCCCCCCCCCICCCCCN

NNNCICINNICNININIIINNNIIIINNNNNCN

ICCNCCNCCNCNNCCNCCCCCCCCCCNCCCCCI

ICIICCNCNCNCICCNICICCCCICCCNCCCNI

CCCICCICCCCCCCCCCCCCCCCCCCCCCCCNC

CINNCCICCNCCIICINCCCCCCCCCCICCCCC

CCNNCNNNCCNNCCNCCNCCCCCNCCCCCNCNI

CCINCCIICCCNICCNIIIICICCCCCCCCIIC

CCCICCNCNNINCCINCCCCCCCCCCCCINCCN

CCCNNCNCNNNCNCNNCCCCCCCCCCICINCCC

NCCNCCNCCNCNCNCNCCCCCCCCCCNCCCNCN

NNCNNNNNCNNCNNNNCNCCNCCNCCICCCCNN

IV Compatibilities The IV compatibility table provides data when 2 or more medications are given into a Y-site of administration. The data in this table largely represent physical incompatibilities (e.g., haze, precipitate, change in color). Therapeutic incompatibilities have not been included, so when using the table, professional judgment should be exercised.

C Ph

ysic

ally

com

patib

le v

ia Y

-site

adm

inis

trat

ion.

I

Phys

ical

ly in

com

patib

le.

N In

form

atio

n on

com

patib

ility

not

ava

ilabl

e or

con

fl ict

ing

Dext

rose

5%

Sodi

um C

hlor

ide

Acyc

lovi

r

Amik

acin

Amio

daro

ne

Azith

rom

ycin

Aztre

onam

Bum

etan

ide

Calc

ium

chl

orid

e

Calc

ium

glu

cona

te

Cefa

zolin

Cefe

pim

e

Ceftr

iaxo

ne

Cim

etid

ine

Cipr

oflo

xaci

n

Cisa

tracu

rium

Dexa

met

haso

ne

Digo

xin

Dilti

azem

Diph

enhy

dram

ine

Dobu

tam

ine

Dopa

min

e

Enal

april

Epin

ephr

ine

Esm

olol

Fam

otid

ine

Fent

anyl

Fluc

onaz

ole

Furo

sem

ide

Gent

amic

in

Hepa

rin

Hydr

ocor

tison

e

Hydr

omor

phon

e

Imip

enem

Insu

lin, R

egul

ar

Keto

rola

c

Labe

talo

l

Lans

opra

zole

Levo

floxa

cin

Line

zolid

Lore

zepa

m

Mag

nesi

um S

O 4

Man

nito

l

Mer

open

em

Met

hylp

redn

isol

one

Met

oclo

pram

ide

Met

opro

lol

Met

roni

dazo

le

Mid

azol

am

Milr

inon

e

Mor

phin

e

Mul

tivita

min

s

Nitro

glyc

erin

Nitro

prus

side

Nore

pine

phrin

e

Onda

nset

ron

Pant

opra

zole

Phen

ylep

hrin

e

Pipe

raci

llin/

Tazo

bact

am

Pota

ssiu

m C

hlor

ide

Prop

ofol

Rani

tidin

e

Sodi

um B

icar

bona

te

Tobr

amyc

in

Vanc

omyc

in

Vaso

pres

sin

Vecu

roni

um

KetorolacLabetalolLansoprazoleLevofloxacinLinezolidLorazepamMagnesium SO4MannitolMeropenemMethylprednisoloneMetoclopramideMetoprololMetronidazoleMidazolamMilrinoneMorphineMultivitaminsNitroglycerinNitroprussideNorepinephrineOndansetronPantoprazolePhenylephrinePiperacillin/TazobactamPotassium ChloridePropofolRantidineSodium BicarbonateTobramycinVancomycinVasopressinVecuronium

CCCCCCCCICCCCCCCCCCCCCCCCCCCCCCC

CCCCCCCCCCCCCCCCCCCNCCCCCNCCCCCC

NINICCCCICCNCICINCININIICCCCCCNN

NCCCCCCCNCCNCCCCNCCCCNCCCICCCCCN

NCNICCNNNCNNNCCCNCNCNNCICNNICCCC

INNINNNNNNNNNNNINNNNCCNIINNNINNN

NCICCICCNCCNICNCNCCCCICCCCCCCNCN

NCNCCCCCNCCNNICCNCCCCCCCCCNCCCCN

NNNNNNINNNNNNNCCCNCCNINNIININNNN

NCICCCCCCINNNCCCNCCCCNCCCCNICCCN

NNIICCNCNCCNCCCCICCCCNCNCCCCNNCC

NNICCCIINCINCICINNNNIINCCNCCNNNN

NICCNCICNCCNCCNCNCCCNCCNCCNCINCN

NCNCCCNNCCNCCCCCNNCNCNNCCCNNNCNC

NNINCCINNICNCCCNNNNCCINICICICNCN

CNNNCCCCNICNCCNCNCICCNCCCICCCCNN

CICCCCCCCCCNNICCCCCCCICCCCNCINCN

NNNNCNNNCNNNNCCCNNNNNNNNCICNNNNN

NCICCCCCCICNCCCCNCCCCICICNCICCCC

NCICCCCCCICNNCNCNCICCICCCCNICCCN

NCICCCNCCCCNNICCNCNCCICICCCICCCC

NCICCCCCCCCNCCCCNCCCCNCCCCCICCCC

NCICCCCCCCCNCCCCNCCCCNCCCCCCCCCN

NCNCCCCCNCCNNCCCCCCCCNCCCCCICCCC

NCICCCCCNNCNCCNCNCCCCICCCCCCCCCC

NCICCCCCNCCNNCNCNCCCCICICCNCCCCN

CCCCCCCCNCCNNCCCNCCCCICCCCCCCCCC

NCCCCCCCCCCNCCNCNCCCCICCCCCCCCCC

NNIICCNCCCINNIIINCCNINNCCCCCCINI

NCCCCCCCCCCNNCCCCCCCCNCNCICCCCCC

NNCICCCCCCCNCCCNNCCCCNCCCCCCIICC

NIICCCNCNNCNCINNNCCCCNCCCCNCNNCC

CCICCCCCCCCNCCCCNCCCCNCCCCCICCNC

NCICCICINCCNNIICNCNCCCCNNCNICCCN

NINICCCCCCCNNNCNNCCINNIICCICNCNN

NNNNCNINNNNNNNCNNNNNNNNNNNNNNNN

NICCCCCNCCNCCCNNCCCCICICCCNCCCC

NI

INIICNIINIINININNINICINNIIINN

NCI

CNCNNCCNCCNCNIINCICICINCCCNN

NCNCCCCCCCNCCNCNCCCCICCCNCCCCCC

CCINCCCCCCNCCCCNCCCIICCCCCCCCCC

NCICCCCCICNCCCCNCCCCNCCCCNNCCCN

ICCNCCCICCNNCNCICCCCNCCCCNCCCCN

NNNNCCCI

NCNNNCCNNNCINNNNNCINCCN

NCICCCICNCNCCCCNCCCIICCNICCCCCN

NCICCCCCCCNNCNCCCCCCNCCCICCCCCN

NNNNNNNNNNNNNNCNNNNNNNNNNNNNNNN

NCICCCCNNCNNCCCNNNNNINCNNNNNNCN

NCICCCCCNCCNCCCNCCCCICICNCICCCC

NCNNNCCNCCNNCCCNCCCNNNCCCCCCCCC

CNICCCCCCCCCCCCNCCCCNCCCNCNCCCC

NNNNNNNINNCNNNNNNNCNNNNNNNNNNNN

NCIICCCCNCCNNCCCNCCCNCCCCCCCCCC

NCNICCCCNCCNNCCCNCCCNCCCCCCCCCC

NCNNCCCCCCCNNCCCCCCCNCCCCCICCCC

NCICCICCIICNNCNCNCCCICCCCCICCCN

NINIIINNNINNIINNNNNNI

CNCNNNNNCN

NCICCCCCNCCNNCNCNCCCCCCCNNCCCCN

NICICCCCNCCNCICCNCCCCNCCNCCIICN

NCICCCCCNNCNNCCCNCCCCCCCCCCCCCN

NCNINCCCNIINNNCNNCCCCNNNCCCINNC

NCNNCCNNCCCNNCCCNCCCCNNCCCNNCNC

NNICCCNCICCNNICNCCCIINCCCCNCNCN

NCICCCCCNCCNNCCCNCCCCNCICINCCCN

NCICCCCCCCCNNCCCNCCCCNCICNCNCCC

NCNNCCCCCCCNCCCCNCCCCCCCCNNCCCN

NCNNCCNNNNNNNCCCNCCCNNNNNCCNNCN

IV CompatibilitiesThe IV compatibility table provides data when 2 or more medications are given into a Y-site of administration. The data in this table largely represent physical incompatibilities (e.g., haze, precipitate, change in color). Therapeutic incompatibilities have not been included, so when using the table, professional judgment should be exercised.

C Ph

ysic

ally

com

patib

le v

ia Y

-site

adm

inis

trat

ion.

I Ph

ysic

ally

inco

mpa

tible

.N

Info

rmat

ion

on c

ompa

tibili

ty n

ot a

vaila

ble

or c

onfl i

ctin

g